Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and
azacitidine for treatment of subjects with previously treated or untreated with high risk
factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy
for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.
Additional locations may be listed on ClinicalTrials.gov for NCT05001828.
See trial information on ClinicalTrials.gov for a list of participating sites.
This is an open label, single arm, phase 1 trial with recommended phase 2 dose (RP2D)
cohorts based on subject inclusion criteria.
Lead In: 6 patients will be enrolled to be treated with standard dose of azacitidine and
venetoclax and the expected RP2D of ADI-PEG 20 (dose level 0). In case of DLT occurring
in >1 patient in cycle 1, 6 additional patients will be accrued at dose level -1 of
ADI-PEG 20 while keeping the doses of azacitidine and venetoclax unchanged (Dose level
-1). Enrollment to cohort 1 and 2 will start after ≤1 patient out of 6 encounters DLT in
cycle 1 at one of these dose levels. The 6 patients enrolled at that dose level will be
counted for efficacy analysis. Cohort 1: Relapsed or refractory AML: target response 25%.
Historical expectation for venetoclax and azacitidine is 15%.
Cohort 2: Newly diagnosed high risk AML: Target response 55%. Historical expectation for
venetoclax and azacitidine is 40%.
Treatment may be continued for a maximum of 24 cycles or 104 doses of ADI-PEG 20 (study
Week 103), whichever is reached first.
Lead OrganizationPolaris Group
